Search filters

Filters
Clear All

Phase

  • 2
  • 2
  • 1
  • 5
  • 2
  • 5

Found 5 Peripheral Vascular Disease trials

A listing of Peripheral Vascular Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)
18 years - 80 years
All genders
Phase 3
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
 STRIDE Study : The Effects of semaglutide on functional capacity in pith type 2 diabetes and peripheral arterial disease
18 years - 99 years
All genders
Phase 3
This is a 52 week, randomized, double-blind, placebo-controlled trial comparing semaglutide 1 mg versus placebo both added to standard of care and administered once weekly in subjects with Type 2 Diabetes Mellitus with Intermittent Claudication.
 A Phase II  Randomized  Double-Blind  Multicenter  Multinational  Placebo-Controlled  Parallel-Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects with Intermittent Claudication (IC)
1 years - 99 years
All genders
Phase 2
In this research study an investigational product called PLX-PAD will be tested to see if it helps claudication. PLX-PAD is made up of mesenchymal-like stromal cells (MSCs), which are similar to stem cells. These cells come from a human placenta (afterbirth) from chosen female donor volunteers. From animal experiments it …
 A Phase 2  Multi-center  Randomized  Double-Blind  Placebo-Controlled  Dose Range Finding Study to Evaluate the Safety  Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects who have Diabetic Foot Ulcer with Peripheral Arterial Disease
1 years - 99 years
All genders
Phase 2
This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have DFU with PAD. The study will enroll approximately 24 subjects. Two dose levels of PDA-002 (3 x 106 and 30 x 106 cells) versus placebo will be evaluated in 1:1:1 randomization approach. Subjects will …
18 years or above
All genders
Observational
This study will be a retrospective chart review of patients who have been diagnosed with benign or malignant pancreatic disease under the practice of Dr. Rohan Jeyarajah, M.D., Dr. Houssam Osman M.D., and Dr. Edward Cho M.D., Sc.M. at Methodist Health System Hospital in Richardson, TX. The Investigators plan to …